Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, including CAD-9303, a NMDAr-PAM, and MIJ-821, a NMDAr-NAM, which is currently being developed by Novartis under a 2015 license agreement.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that management will present at the William Blair Biotech Focus Conference on Thursday, August 6, 2020

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2:00-2:25 pm ET.

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.